Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Assessment of the efficacy of a feed additive consisting of Limosilactobacillus reuteri (formerly Lactobacillus reuteri) DSM 32203 for dogs (NBF LANES)

  • 2022-07
  • EFSA Journal 20(7)
    • V. Bampidis
    • G. Azimonti
    • M. Bastos
    • Henrik Christensen
    • B. Dusemund
    • Mojca Fašmon Durjava
    • M. Kouba
    • M. López-Alonso
    • Secundino López Puente
    • F. Marcon
    • B. Mayo
    • A. Pechová
    • M. Petkova
    • F. Ramos
    • Yolanda Sanz
    • R. Villa
    • R. Woutersen
    • G. Martelli
    • M. Anguita
    • Rosella Brozzi
    • J. Galobart
    • J. Ortuño
    • J. Revez

Abstract

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the efficacy of Limosilactobacillus reuteri (formerly Lactobacillus reuteri) DSM 32203 as a zootechnical additive for dogs. The additive is a preparation of viable cells of L. reuteri DSM 32203 and it has not been previously authorised as a feed additive in the European Union. The additive is intended for use in complete feed for dogs at a minimum use level of 6 × 109 colony forming units (CFU) per animal and day. In a previous opinion, the FEEDAP Panel could not conclude on the efficacy of L. reuteri DSM 32203 for dogs. The applicant has provided supplementary information to support the efficacy of the additive to dogs. Based on the data provided, the FEEDAP Panel concludes that L. reuteri DSM 32203 has the potential to improve faecal consistency by reducing the moisture content of stools from dogs receiving the additive at 1 × 1010 CFU/kg feed. However, the Panel has some reservations on the effects in the moisture content of stools, which if maintained over time might cast doubts on the benefits on the long-term use of the additive since it could lead to constipation.

Keywords: Limosilactobacillus reuteri DSM 32203; NBF‐1; dogs; efficacy; gut flora stabilisers; zootechnical additives.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Limosilactobacillus reuteri 1E1Improved Stool ConsistencyBeneficial
Moderate
Limosilactobacillus reuteri 1E1Increased Constipation RiskHarmful
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Join Our Community
Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.